mci 9038 has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akita, N; Asanuma, K; Asanuma, Y; Hayashi, T; Matsumine, A; Okamoto, T; Sudo, A; Uchida, A; Wakabayashi, H; Yoshikawa, T | 1 |
| Al-Katib, W; Allan, AL; Chambers, AF; Goodale, D; Hedley, BD; Postenka, CO; Schulze, EB; Tuck, AB | 1 |
2 other study(ies) available for mci 9038 and Breast Neoplasms
| Article | Year |
|---|---|
The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone.
Topics: Animals; Antithrombins; Arginine; Body Weight; Bone Neoplasms; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mice; Pipecolic Acids; Sulfonamides; Thrombin; Thromboplastin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms.
Topics: Animals; Anticoagulants; Arginine; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Osteopontin; Pipecolic Acids; Platelet Aggregation Inhibitors; Receptors, Thrombin; Sulfonamides; Thrombin | 2008 |